Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences

Circ Heart Fail. 2022 Sep;15(9):e009629. doi: 10.1161/CIRCHEARTFAILURE.122.009629. Epub 2022 Jun 3.

¹ Department of Molecular Pharmacology and Experimental Therapeutics (T.T.L.N., D.L., V.M., R.M.W., N.L.P.), Mayo Clinic, Rochester, MN.
² Graduate School of Biomedical Sciences (T.T.L.N.), Mayo Clinic, Rochester, MN.
³ Department of Cardiovascular Medicine (M.W., S.I., H.M.G.B., N.A., V.M., S.S., J.C.B., M.R., N.L.P.), Mayo Clinic, Rochester, MN.
⁴ Internal Medicine, The Wright Center, Scranton, PA (S.S.).
⁵ Division of General Internal Medicine, Palliative Medicine and Medical Education, University of Louisville, KY (V.D.).
⁶ Divisions of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences (K.R.B.), Mayo Clinic, Rochester, MN.

No abstract available

Keywords: biomarker; heart failure; proteomics; sacubitril; sex differences; valsartan.

Publication types